[Extrapyramidal syndrome].
Nakagawa
Shin
S
Department of Psychiatry, Hokkaido University Graduate School of Medicine.
Koyama
Tsukasa
T
D000208:Acute Disease; D017109:Akathisia, Drug-Induced / Q000209:etiology; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000145:classification; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D004421:Dystonia / Q000139:chemically induced; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology; D054833:Isoindoles; D020734:Parkinsonian Disorders / Q000139:chemically induced; D000069348:Quetiapine Fumarate; D011976:Receptors, Muscarinic; D011985:Receptors, Serotonin; D018967:Risperidone / Q000009:adverse effects / Q000494:pharmacology; D012702:Serotonin Antagonists; D013577:Syndrome; D013844:Thiazoles / Q000009:adverse effects / Q000494:pharmacology
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D065127:Dopamine D2 Receptor Antagonists; D007211:Indoles; D054833:Isoindoles; D011976:Receptors, Muscarinic; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D013844:Thiazoles; D000069348:Quetiapine Fumarate; D018967:Risperidone; C065533:perospirone